YOLFTbeta
30

ChengDa Pharmaceuticals Co. Ltd.

301201 · SHE · Healthcare / Drug Manufacturers - Specialty & Generic

23.26CNY-0.90 (-3.73%)

Price History

Full chart

Market Stats

Previous Close24.16
Open23.89
Day Range23.22 – 24.71
52-Week Range26.90 – 64.68
Volume3.25M
Market Cap4.72B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.15
Dividend Yield0.66%
Beta-0.19
50-Day Avg33.48
200-Day Avg39.09

About

ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients, and food and feed additives in China and internationally. It offers process research and development, process optimization, quality and stability research, customized production and other services for pharmaceutical intermediates and APIs; and food and feed additives, such as L-carnitine and L-carnitine tartrate. The company also provides bulk drug products, including urogenital, nervous system, blood and hematopoietic organs, musculoskeletal system, digestive tract and metabolism, antineoplastic and immunomodulators; and pharmaceutical intermediates comprising drug intermediates for blood and hematopoietic organs, drug intermediates in digestive tract and metabolism, and nervous system drug intermediates. ChengDa Pharmaceuticals Co., Ltd. was founded in 1980 and is based in Jiaxing, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Gang Lu
  • Employees694
  • HeadquartersNo. 36, Huanghe Road, Jiaxing, China, 314100, China
  • Websitehttps://www.chengdapharm.com

Leadership

  • Mr. Gang LuGM & Director · b. 1975
  • Mr. Honglin HuangDeputy GM & Director · b. 1962
  • Ms. Jin LuDeputy GM & Director · b. 1978
  • Ms. Xiaojing YangDeputy GM & Secretary · b. 1982
  • Mr. Chao FeiChief Financial Officer & Chief Accountant · b. 1979
  • Mr. Zhiyong PengDeputy General Manager · b. 1980
  • Mr. Bao HuDeputy General Manager · b. 1983
  • Ms. Min Wei ZhaoDeputy General Manager · b. 1983

Financials

Income Statement

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue293.97M373.04M415.73M411.46M414.30M333.13M406.37M
Growth (%)-+26.89%+11.44%-1.03%+0.69%-19.59%+21.99%
Cost of Revenue161.54M186.06M207.98M213.93M236.62M190.48M226.87M
Gross Profit132.43M186.98M207.75M197.54M177.68M142.65M179.50M
Gross Margin45.05%50.12%49.97%48.01%42.89%42.82%44.17%
Operating Expense60.70M83.05M84.98M107.80M117.06M200.77M166.01M
Operating Income71.73M103.93M122.77M89.74M60.62M-58.12M13.48M
Operating Margin24.40%27.86%29.53%21.81%14.63%-17.45%3.32%
EBITDA131.32M176.56M147.17M155.62M144.85M20.27M61.98M
EBITDA Margin44.67%47.33%35.40%37.82%34.96%6.08%15.25%
Net Income54.22M121.17M100.44M106.48M90.98M-28.10M-11.93M
Net Income Margin18.45%32.48%24.16%25.88%21.96%-8.44%-2.93%
R&D12.11M18.98M17.22M19.44M27.46M93.71M40.18M
R&D as % of Total Revenue4.12%5.09%4.14%4.73%6.63%28.13%9.89%
Interest Expense41.69M2.68M1.40M198.48K0295.34K2.28M
Interest Expense % of Total Revenue14.18%0.72%0.34%0.05%0.00%0.09%0.56%

Balance Sheet

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets546.56M534.21M683.23M2.32B2.46B2.44B2.35B
Total Liabilities189.21M75.30M153.30M105.81M176.40M290.77M252.83M
Total Equity356.14M458.06M529.24M2.21B2.28B2.14B2.09B
Cash65.61M47.02M18.49M604.43M1.36B178.46M725.80M
Net Debt55.07M-35.56M----

Cash Flow

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow67.52M128.97M83.14M47.67M192.07M28.65M34.02M
Capital Expenditure51.06M63.81M138.70M205.69M224.67M286.36M69.02M
Free Cash Flow16.46M65.16M-55.56M-158.03M-32.60M-257.72M-35.00M
Dividends Paid28.53M22.84M31.34M43.79M29.01M30.55M32.82M
FCF to OCF24.38%50.52%-66.83%-331.53%-16.97%-899.59%-102.89%
Dividend Paid to FCF173.35%35.06%-56.40%-27.71%-88.99%-11.85%-93.77%

Earnings

Report DateMar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------------------
EPS Actual0.170.250.170.090.130.060.210.190.120.040.10-0.45-0.010.090.03-0.190.05-0.03
Surprise------------------
Timing------------------

Key Statistics & Ratios

Market Cap4.72B
Enterprise Value4.14B
Trailing P/E0.00
Forward P/E0.00
Price / Sales9.84
Price / Book2.42
EPS-0.15
Book Value13.84
Revenue (TTM)479.41M
Gross Profit (TTM)132.42M
EBITDA53.08M
Profit Margin-4.68%
Operating Margin-3.09%
Return on Equity-1.07%
Return on Assets-0.57%
Shares Outstanding154.71M
Shares Float80.79M
Beta-0.19
Dividend Yield0.66%
Dividend Rate0.20
Payout Ratio43.67%

Dividends

20261×
0.20Jul 15, 2026
20251×
0.20Jul 10, 2025
20241×
0.20Jul 10, 2024
20231×
0.30Jul 7, 2023
20221×
0.28May 27, 2022

Stock Splits

  • Jul 7, 20231.6:1